The advancement of GIPR/GLP-1R dual agoniststo late-stage clinical trials has further highlighted the therapeutic potential ofGIPR agonism, with dual incretin receptor agonists demonstrating enhanced glycaemiccontrol and weight loss in patients with T2D (Friaset al., 2018). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.